Summary
This 8-K filing by BeOne Medicines Ltd. (ONC) reports two significant developments regarding their drug BRUKINSA® (zanubrutinib). First, on October 12, 2022, BeiGene announced that the Phase 3 ALPINE trial demonstrated superior Progression-Free Survival (PFS) for BRUKINSA® compared to IMBRUVICA® (ibrutinib), as assessed by both independent review committee and investigator. This outcome is a crucial indicator of the drug's efficacy in managing chronic lymphocytic leukemia (CLL). Second, on October 14, 2022, BeiGene announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of BRUKINSA® for the treatment of adult patients with CLL. This positive opinion is a strong precursor to potential market approval in Europe, signifying a major regulatory milestone for the drug and expanding its commercial prospects.
Key Highlights
- 1BeiGene announced superior Progression-Free Survival (PFS) in the Phase 3 ALPINE trial for BRUKINSA® (zanubrutinib) compared to IMBRUVICA® (ibrutinib).
- 2The positive PFS results were confirmed by both an independent review committee (IRC) and the trial investigator.
- 3The ALPINE trial focused on the treatment of adult patients with chronic lymphocytic leukemia (CLL).
- 4The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for BRUKINSA® in CLL.
- 5This CHMP opinion signifies a key regulatory step towards market access for BRUKINSA® in Europe.
- 6The filing includes press releases detailing these advancements as exhibits.